BioTech IP Review

Lipid nanoparticle (LNP) technology for mRNA delivery

U.S. Patent No. 11,246,933

Issued: February 2022
Assignee: Typically assigned to parties controlling foundational LNP technology asserted against Pfizer, BioNTech, and Moderna (e.g., Alnylam’s biomaterial patents)
Focus: Biodegradable cationic lipid compositions and related LNP delivery technology used for delivering messenger RNA (mRNA) into cells — the core enabling technology for Comirnaty.

This patent is one of the groundbreaking LNP patents that different biotech companies, including Pfizer and Moderna, have defended or been accused of infringing in litigation over mRNA vaccine delivery systems. In 2022, Alnylam Pharmaceuticals filed a lawsuit alleging that Comirnaty infringed this patent and related ones covering lipid delivery technology, reflecting the massive commercial and technical value of LNP delivery methods crucial for mRNA vaccines.

What This Patent Covers

Although not filed by Pfizer itself, U.S. 11,246,933 and related patents asserted in 2022 focus on:

  • Biodegradable cationic lipids that form LNPs capable of encapsulating mRNA and delivering it into cells with reduced toxicity.
  • Methods of formulating these lipids such that mRNA cargo is protected, efficiently delivered to target cells, and released in a way that yields strong protein expression — critical for vaccine efficacy.
  • These kinds of lipid nanoparticle compositions are central to the performance of Comirnaty and similar mRNA vaccines because they facilitate mRNA entry into human cells and minimize immune over‑reaction.

Although the specific patent mentioned (11,246,933) may not have been invented by Pfizer, it was asserted against Pfizer’s vaccine in litigation filed in 2022 — underscoring the enormous worth of the underlying LNP technology to Pfizer’s COVID‑19 vaccine success and its legal strategy to defend this core IP area.

Why It’s Important

1. Central to the mRNA Vaccine Platform

The composition and delivery of mRNA via lipid nanoparticles is what enables Pfizer–BioNTech’s Comirnaty® vaccine to work in humans, protecting billions of people worldwide and generating tens of billions of dollars in revenue since its rollout. The delivery technology is just as commercially critical as the mRNA sequence itself.

2. Strategic IP in the mRNA Era

The intense litigation over this LNP patent and similar patents — including actions brought by Alnylam against Pfizer/BioNTech in 2022 — highlights how foundational LNP technology is perceived by industry players. Companies with strong proprietary lipids can command licensing, royalties, or settlements tied to huge vaccine sales.

3. Competitive & Legal Significance

Defending or licensing such patents helps Pfizer secure freedom to operate for current and next‑generation mRNA vaccines (e.g., influenza, RSV, cancer indications). The disputes around these LNP patents reflect ongoing battles over rights to essential biotech platforms.

Summary

  • Patent in Focus: U.S. Patent No. 11,246,933 — biodegradable cationic lipid/LNP technology
  • Issued: February 2022
  • Relevance: This category of patents was centrally involved in patent litigation surrounding Pfizer–BioNTech’s Comirnaty® COVID‑19 vaccine in 2022, illustrating how vital LNP delivery technology is to mRNA vaccine performance and Pfizer’s biotech IP strategy.

Although this particular patent isn’t a classic Pfizer‑owned issued patent, it represented one of the most critical IP assets asserted in relation to Pfizer’s vaccine revenues and legal positioning — and therefore is among the most commercially consequential patents in the biotech landscape involving Pfizer that year.

Leave a comment